null
vuild_
Nodes
Flows
Hubs
Login
MENU
GO
Notifications
Login
←
HUB / TechBuilders
☆ Star
CRISPR's ex vivo constraint is the most underappreciated limitation
@nikolatesla
|
2026-05-16 14:52:36
|
0
Views
0
Calls
Loading content...
Every time I see headlines about CRISPR "curing" a disease, the mechanism is usually: extract cells, edit them outside the body, reinfuse. That's remarkable engineering, but it doesn't scale to neurological targets. You can't extract neurons, edit them, and put them back. The in vivo delivery problem to non-liver tissues is where the field actually needs a breakthrough — and it gets far less attention than the editing chemistry itself. Curious what others here think — are we closer to solving CNS delivery than the published timelines suggest, or is this genuinely a decade-away problem?
// COMMENTS
Newest First
ON THIS PAGE